По вашему запросу найдено документов: 314

Страница 1 из 32

EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH COMPLETE DATABASE RESULTS OF A PHASE 2 STUDY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Zelinska, N., Skorodok, J., Skorodok, J., Malievsky, O., Rosenfeld, R.G., Zadik, Z., Koren, R., Vander, S., Hart, G., Raduk, D. (2016)
EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH
SAFETY AND TOLERABILITY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH COMPLETE DATASET RESULTS OF A PHASE 2 STUDY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Zelinska, N., Skorodokb, J., Malievsky, O., Rosenfeldd, Ron G., Zadike, Zvi, Korenf, R., Vanderf, Sh., Hartf, G., Radziukg, K. (2016)
-modified human GH (hGH) developed for once-weekly administration in growth hormone deficient (GHD) adults
12-Month Effects of Once-Weekly and Twice-Monthly Administration of Hybrid Fc-Fused Human Growth Hormone, GX-H9, Treatment in Pediatric with GHD Deficiency
Malieyskiy, O., Mykola, A., Nataliya, Z., Bolshova, E.V., Senatorova, G., Oroszlan, G., Skorodok, J., Peterkova, V., Nataliya, C., Sorokman, T., Yang, S., Lee, J.E., Muzsnai, A., Hwang, J.S., Lee, S.Y., Choi, Y.J., Ji, H.J., Woo, J., Sung, Y.C. (2018)
®. Twelve-month effects of once-weekly, twice-monthly administration of GX-H9 and daily Genotropin® were
An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
Zadik, Zvi, Zelinska, Nataliya, Iotova, Violeta, Skorodok, Yulia, Malievsky, Oleg, Mauras, Nelly, Valluri, Srinivas Rao, Pastrak, Aleksandra, Rosenfeld, Ron (2023)
Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) employed as a once-weekly
A HYBRID FC-FUSED HUMAN GROWTH HORMONE, GX-H9, SHOWS A POTENTIAL FOR WEEKLY AND TWICE-MONTHLY ADMINISTRATION IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Mykola, A., Malievskiy, O, Nataliya, Z, Bolshova, EV, Senatorova, G, Oroszlan, G, Skorodok, J, Peterkova, V, Nataliya, C, Sorokman, T, Yang, S, Lee, JE, Muzsnai, A, Hwang, JS, Kim, T, Choi, YJ, Woo, J, Jang, WI, Sung, YC, Keyoung, M (2017)
A HYBRID FC-FUSED HUMAN GROWTH HORMONE, GX-H9, SHOWS A POTENTIAL FOR WEEKLY AND TWICE
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
for once-weekly treatment of children with growth hormone deficiency (GHD). Objective: We aimed to compare
Возможности иммунотерапии метастатического рака шейки матки
Immunotherapeutic options for management of metastatic cervical cancer
Menshikov, Konstantin V., Sultanbaev, Alexander V., Musin, Shamil I., Menshikovа, Irina А., Sultanbaeva, Nadezda I., Chashchin, Aleksandr V., Lipatov, Danila О., Izmailov, Adel А., Меньшиков, К.В., Султанбаев, А.В., Мусин, Ш.И., Меньшикова, И.А., Султанбаева, Н.И., Чащин, В.А., Липатов, Д.О., Измайлов, А.А. (2023)
Assessment of the 3-substituted thietane-1,1-dioxide derivative antidepressant effect using rat model of depression induced by reserpine
Nikitina, Irina L., Gaisina, Gulnara G., Klen, Elena E., Tkachenko, Lyubov A. (2025)
significant antidepressant properties when administered intraperitoneally (i.p.) to mice once or repeatedly
Характеристика гистологической структуры тканей зуба при экспериментальном гипотиреозе и введении йодстевиолгликозида
characteristics of the histological structure of tooth tissues in experimental hypothyroidism and administration of iodsteviolglycoside
Ganeev, T.I., Kamilov, F.H, Kozlov, V.N, Farshatova, E.R., Sirak, S.V., Sirak, A.G., Shaymardanov, T.N., Ганеев, Т. И., Камилов, Ф. Х., Фаршатова, Е. Р., Сирак, С. В., Сирак, А. Г., Шаймарданов, Т. Н. (2024)
and administration of iodsteviolglycoside
Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration
Umezawa, K, Breborowicz, A., Gantsev, S. (2020)
that IP administration never increased the blood concentration of DHMEQ because of the instability

Страница 1 из 32

Google Scholar
OpenDoar

Фасеты

Научный руководитель
Авторы
Ключевые слова
Год